White Paper
Increasing the Bioavailability of Oncology Drugs
![Increasing the Bioavailability of Oncology Drugs](/var/wrbm_gb_food_pharma/storage/images/_aliases/wrbm_product_file/publications/pharmaceutical-science/outsourcing-pharma.com/library/increasing-the-bioavailability-of-oncology-drugs/16920108-1-eng-GB/Increasing-the-Bioavailability-of-Oncology-Drugs.png)
Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract. Most crystalline TKI drugs have pH-dependent solubility that affects their bioavailability in an oral dosage form.
This white paper outlines the challenges associated with pH-dependent solubility for oral TKI drugs and reviews how leveraging ASD formulation can help create more effective, patient-friendly drug products.